BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 24332643)

  • 1. Evaluation of a new quantitative point-of-care test platform for urine-based detection of bladder cancer.
    Ritter R; Hennenlotter J; Kühs U; Hofmann U; Aufderklamm S; Blutbacher P; Deja A; Hohneder A; Gerber V; Gakis G; Stenzl A; Schwentner C; Todenhöfer T
    Urol Oncol; 2014 Apr; 32(3):337-44. PubMed ID: 24332643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preliminary Results of a Multicentre Study of the UBC Rapid Test for Detection of Urinary Bladder Cancer.
    Ecke TH; Arndt C; Stephan C; Hallmann S; Lux O; Otto T; Ruttloff J; Gerullis H
    Anticancer Res; 2015 May; 35(5):2651-5. PubMed ID: 25964541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
    May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B
    Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BTA stat®, NMP22® BladderChek®, UBC® Rapid Test, and CancerCheck® UBC® rapid VISUAL as urinary marker for bladder cancer: Final results of a German multicenter study.
    Ecke TH; Meisl CJ; Schlomm T; Rabien A; Labonté F; Rong D; Hofbauer S; Friedersdorff F; Sommerfeldt L; Gagel N; Gössl A; Barski D; Otto T; Grunewald CM; Niegisch G; Hennig MJP; Kramer MW; Koch S; Roggisch J; Hallmann S; Weiß S; Waldner M; Graff J; Veltrup E; Linden F; Hake R; Eidt S; Wirtz RM
    Urol Oncol; 2023 Dec; 41(12):484.e17-484.e26. PubMed ID: 37407421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear matrix protein 22 for bladder cancer detection: comparative analysis of the BladderChek® and ELISA.
    Hatzichristodoulou G; Kübler H; Schwaibold H; Wagenpfeil S; Eibauer C; Hofer C; Gschwend J; Treiber U
    Anticancer Res; 2012 Nov; 32(11):5093-7. PubMed ID: 23155286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. UBC
    Ecke TH; Weiß S; Stephan C; Hallmann S; Barski D; Otto T; Gerullis H
    Tumour Biol; 2017 May; 39(5):1010428317701624. PubMed ID: 28468590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Qualitative and quantitative assessment of urinary cytokeratin 8 and 18 fragments compared with voided urine cytology in diagnosis of bladder carcinoma.
    Hakenberg OW; Fuessel S; Richter K; Froehner M; Oehlschlaeger S; Rathert P; Meye A; Wirth MP
    Urology; 2004 Dec; 64(6):1121-6. PubMed ID: 15596183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II (UBC II) test in early recurrent transitional cell carcinoma of the bladder.
    Kibar Y; Goktas S; Kilic S; Yaman H; Onguru O; Peker AF
    Ann Clin Lab Sci; 2006; 36(1):31-8. PubMed ID: 16501234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative analysis of sensitivity to blood in the urine for urine-based point-of-care assays (UBC rapid, NMP22 BladderChek and BTA-stat) in primary diagnosis of bladder carcinoma. Interference of blood on the results of urine-based POC tests.
    Lüdecke G; Pilatz A; Hauptmann A; Bschleipfer T; Weidner W
    Anticancer Res; 2012 May; 32(5):2015-8. PubMed ID: 22593481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. UBC
    Ecke TH; Weiß S; Stephan C; Hallmann S; Arndt C; Barski D; Otto T; Gerullis H
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30513851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical value of combined detection with urinary bladder cancer antigen, hyaluronic acid and cytokeratin 20 in diagnosis of bladder cancer].
    Pu XY; Wang ZP; Chen YR; Wu YL; Wang HP; Wang XH
    Ai Zheng; 2008 Sep; 27(9):970-3. PubMed ID: 18799038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary NMP22 BladderChek test in the diagnosis of superficial bladder cancer.
    Moonen PM; Kiemeney LA; Witjes JA
    Eur Urol; 2005 Dec; 48(6):951-6; discussion 956. PubMed ID: 16257108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
    Kumar A; Kumar R; Gupta NP
    Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of urine tumor-associated trypsin inhibitor, CYFRA 21-1, and urinary bladder cancer antigen for detection of high-grade bladder carcinoma.
    Gkialas I; Papadopoulos G; Iordanidou L; Stathouros G; Tzavara C; Gregorakis A; Lykourinas M
    Urology; 2008 Nov; 72(5):1159-63. PubMed ID: 18514770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression and clinical significance of nuclear matrix protein 22 and cytokeratin 18 in transitional cell carcinoma of the bladder].
    Song JW; DU LL; Zhao XW; Jing JX; Han CZ; Cui Y; Liu JW; Hao HL; Wang ZG; Mi ZG
    Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):274-7. PubMed ID: 19615282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined application of cytology and molecular urine markers to improve the detection of urothelial carcinoma.
    Todenhöfer T; Hennenlotter J; Esser M; Mohrhardt S; Tews V; Aufderklamm S; Gakis G; Kuehs U; Stenzl A; Schwentner C
    Cancer Cytopathol; 2013 May; 121(5):252-60. PubMed ID: 23172833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study.
    Pichler R; Tulchiner G; Fritz J; Schaefer G; Horninger W; Heidegger I
    Int J Med Sci; 2017; 14(9):811-819. PubMed ID: 28824318
    [No Abstract]   [Full Text] [Related]  

  • 19. A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria.
    O'Sullivan P; Sharples K; Dalphin M; Davidson P; Gilling P; Cambridge L; Harvey J; Toro T; Giles N; Luxmanan C; Alves CF; Yoon HS; Hinder V; Masters J; Kennedy-Smith A; Beaven T; Guilford PJ
    J Urol; 2012 Sep; 188(3):741-7. PubMed ID: 22818138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative detection of cytokeratin 20 mRNA in urine samples as diagnostic tools for bladder cancer by real-time PCR.
    Guo B; Luo C; Xun C; Xie J; Wu X; Pu J
    Exp Oncol; 2009 Mar; 31(1):43-7. PubMed ID: 19300416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.